IRCT20150529022468N5 IRCT 2019-07-30 Iran University of Medical Sciences Comparison of tranexamic acid versus Kligman’s application in the treatment of macular amyloidosis Comparison of efficacy and safety of intra lesional tranexamic acid injection versus topical Kligman’s formula application in the treatment of macular amyloidosis 2018-11-22 anticipated 40 Complete https://irct.ir/trial/40458 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: To select patients randomly, 40 pieces of paper will be numbered from 1 to 40. For each patient one of the papers will be taken in random order. If the number is paired, the patient will be in the tranexamic acid group, and if the number is Odd in the Kligman group, Blinding description: Patients will be evaluated by a physician. This physician will be blind to the grouping of patients. In addition, the data analyzer will be blind to the grouping of patients. 2-3 Macular amyloidosis. Intervention 1: Intervention group: tranexamic acid. Six sessions of treatment every two weeks are given by the physician as an intra lesional tranexamic acid. Each session, 0.1 cc of 4 mg / ml tranexamic acid will be injected interdermally with a 30-G needle and at a distance of 1 cm to an area of 10*10 cm which covers the entire lesion area. Intervention 2: Intervention group: Kligman (with hydroquinone 4.0%, tretinoin 0.05%, fluocinolone acetonide 0.01%, vit c 500mg formula). Apply a tip of finger topical Kligman on a dry and clean skin each night for 12 weeks and do not rinse at least 4 hours after application. Yes - There is a plan to make this available What will be shared: All of information without name When: 1 years after publish To whom: Researchers Conditions: All of patients information without their name Where to obtain: Study researcher: Mohammadreza Ghasemi How to obtain: sending email to the researcher: ghassemi.mr@iums.ac.ir Comments: